Safety and Effectiveness of Nivolumab in Recurring Kidney Cancer Participants

Bristol-Myers Squibb (BMS)

Status: Completed

Conditions: Renal Cancer; Kidney Cancer

Treatments: Other: Non-Interventional

Study type: Observational

Funder types: Industry

Identifiers

NCT03568435

CA209-8D3

Details and patient eligibility

About

A non-interventional, medical record review of clinical data collected from Japanese participants with recurring kidney cancer

Enrollment: 212 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• A patient with RCC with distant metastasis treated for the first time with nivolumab

Exclusion criteria

• Patients who have participated in some trials with immuno-checkpoint blockade before or after treatment with nivolumab after diagnosis with RCC

Other protocol defined inclusion/exclusion criteria could apply

Trial design

212 participants in 1 patient group

Participants with metastatic RCC taking nivolumab

Description:

Specified dose on specified day

Treatment:

Other: Non-Interventional